Acorda Therapeutics announces FDA approval of INBRIJA

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

The FDA approves Acorda Therapeutics' (NASDAQ:ACOR) INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.

INBRIJA is expected to be commercially available by prescription in the U.S. in Q1 2019.

The company will host a conference call today at 8:30 a.m. ET.

Subscribe for full text news in your inbox